Award
NIH Reporter #11300208
PhytoSERM Efficacy to Prevent Menopause Associated Decline in Brain Metabolism and Cognition: A Double-Blind, Randomized, Placebo-Controlled Phase 2 Clinical Trial
Recipient
University of Arizona
Award Amount
$1,353,297.00
Ceiling
$1,353,297.00
Awarded
May 25, 2026
Identifier
11300208
This award funds a Phase 2 clinical trial by the University of Arizona to test PhytoSERM's effectiveness in preventing menopause-associated cognitive decline and brain metabolism reduction, aiming to reduce Alzheimer's disease risk in women.
Description
A Phase 2 clinical trial to evaluate the safety, efficacy, and impact of PhytoSERM on Alzheimer's disease risk reduction in women, focusing on brain metabolism, cognition, and various biomarkers and imaging outcomes.